current standards for first-line metastatic hormone-sensitive prostate cancer
Published 2 years ago • 110 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
1:26
current standards and future prospects for the treatment of hormone refractory prostate cancer
-
2:46
first-line treatments in metastatic prostate cancer
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
2:34
first-line treatments for patients with mhspc and mcrpc
-
0:47
systemic triple therapy in metastatic hormone-sensitive prostate cancer
-
2:25
subgroups of metastatic hormone-sensitive prostate cancer (mhspc)
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
2:41
recent developments in treatment options for castration-sensitive metastatic prostate cancer
-
1:15
exciting times for hormone-sensitive prostate cancer treatment
-
1:19
highlights in prostate cancer from esmo
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
3:20
radiation therapy for the local treatment of metastatic hormone-sensitive prostate cancer
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
1:06:24
metastatic hormone sensitive prostate cancer
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
4:40
axel merseburger, esmo 2019 - advances in metastatic hormone-sensitive prostate cancer